PunchAPC rally disruption: SDP rejects Nasarawa claims against Al-Makura, AdamuCNN Türkİzmir'de uyuşturucu operasyonu: 7 gözaltıThe Jerusalem PostDemocracy was top Jewish voter concern in midterms, not Israel or antisemitism - poll한겨레‘AI 공포’에 안전자산으로 몰렸다…금값, 일주일 전보다 5% 넘게 올라ZDF heuteAktuelle Pressemitteilungen des ZDFSouth China Morning PostHow Japan’s 660 most wanted stay hidden: slums, day labour and forged IDsRolling StoneNile Rodgers Defends AI Use in Music Video: ‘We Created Everything … The AI Did What We Told It to Do’매일경제피노, 1830억 원 규모 유증 단행…이차전지 소재 사업 체질 개선Malay MailThe iPhone Duo is my new favourite iPhone but is it for you?The Sydney Morning HeraldBeau Lamarre-Condon trial live updates: Alleged double murderer, former NSW Police officer returns to witness box, asked about relationship with Jesse BairdBillboardAmy Winehouse’s ‘Back to Black’ Reissue Sparks Top 10 Chart ReturnCBS NewsMississippi Senate race is toss-up, with razor-thin margin

KioskNews

The Daily Newsstand · Free, Always
Friday, November 6, 2026
The Newsstand

On the stand now

[특징주] HLB, ‘리보세라닙’ Class2 분류 소식에 20% 급락…연내 허가 기대 꺾였다

미국 식품의약국(FDA)이 HLB의 간암 신약 후보물질 ‘리보세라닙’ 병용요법의 신약허가신청(NDA)을 심사하면서 분류 등급을 Class 2로 지정했다는 소식에 4일 HLB 주가가 20% 가까이 급락하고 있다. 진양곤 HLB그룹 회장이 FDA의 심사 분류를 Class 1로 예상하며 연내 허가 여부가 결정될 수 있다고 밝혔지만, 실제로는 Class 2로 분류

The briefing refreshes every hour. Fresh stories arrive every 10 minutes and stay on the newsstand for 24 hours.